Tokyo-bases R-tech Submits ANDA To U.S. FDA For Glaucoma Drug
This article was originally published in PharmAsia News
Executive Summary
R-Tech Ueno submitted an abbreviated new drug application to U.S. FDA for latanoprost eye drops for glaucoma and ocular hypertension
R-Tech Ueno submitted an abbreviated new drug application to U.S. FDA for latanoprost eye drops for glaucoma and ocular hypertension. The generic version of Pfizer's Xalatan , latanoprost is widely used for reducing ocular hypertension. R-Tech is an ophthalmology specialty drug maker and the company has manufactured and marketed Rescula (unoprostone) eye drops for glaucoma since 1994. (Click here for more - Japanese language) "R-Tech Enters Generics Market With ANDA Submission For Glaucoma Drug"--Nikkei Sangyo News (4/8/2010) |